Pontus Röbeck

Pontus Röbeck

Auto-generated profile, based on publicly available information

Pontus Röbeck

Department of Urology, Uppsala University Hospital, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in The Prostate
Verified
Journal Article
Open access
PRPontus Röbeck
Pontus Röbeck
LXLidi Xu
Lidi Xu
DADilruba Ahmed
Dilruba Ahmed
ADAnca Dragomir
Anca Dragomir
PDPär Dahlman
Pär Dahlman
SLSam Ladjevardi
Sam Ladjevardi
Background: Prostate cancer (PCa) is a highly heterogeneous, multifocal disease, and identification of clinically significant lesions is challenging, which complicates the choice of adequate treatment. The Prostatype® score (P‐score) is intended to guide treatment decisions for newly diagnosed PCa patients based on a three‐gene signature (IGFBP3, F3, and VGLL3) and clinicopathological information obtained at diagnosis. This study evaluated association of the P‐score measured in preoperative magnetic resonance imaging/transrectal ultrasound fusion‐guided core needle biopsies (CNBs) and the P‐score measured in radical prostatectomy (RP) specimens of PCa patients. We also evaluated the P‐score association with the pathology of RP specimens. Furthermore, concordance of the P‐score in paired CNB and RP specimens, as well as in index versus concomitant nonindex tumor foci from the same RP was investigated.Methods: The study included 100 patients with localized PCa. All patients were diagnosed by CNB and underwent RP between 2015 and 2018. Gene expression was assessed with the Prostatype® real‐time quantitative polymerase chain reaction kit and the P‐score was calculated. Patients were categorized into three P‐score risk groups according to previously defined cutoffs.Results: For 71 patients, sufficient CNB tumor material was available for comparison with the RP specimens. The CNB‐based P‐score was associated with the pathological T‐stage in RP specimens (p = 0.02). Moreover, the CNB‐based P‐score groups were in substantial agreement with the RP‐based P‐score groups (weighted κ score: 0.76 [95% confidence interval, 95% CI: 0.60–0.92]; Spearman's rank correlation coefficient r = 0.83 [95% CI: 0.74–0.89]; p < 0.0001). Similarly, the P‐score groups based on paired index tumor and concomitant nonindex tumor foci (n = 64) were also in substantial agreement (weighted κ score: 0.74 [95% CI: 0.57–0.91]; r = 0.83 [95% CI: 0.73–0.89], p < 0.0001).Conclusions: Our findings suggest that the P‐score based on preoperative CNB accurately reflects the pathology of the whole tumor, highlighting its value as a decision support tool for newly diagnosed PCa patients.

20 March 2023 in Cytopathology
Verified
Journal Article
Open access
PRPontus Röbeck
Pontus Röbeck
BFBo Franzén
Bo Franzén
RCRafaele Cantera‐Ahlman
Rafaele Cantera‐Ahlman
ADAnca Dragomir
Anca Dragomir
GAGert Auer
Gert Auer
SLSam Ladjevardi
Sam Ladjevardi
Background: Improved molecular diagnosis is needed in prostate cancer (PC). Fine needle aspiration (FNA) is a minimally invasive biopsy technique, less traumatic compared to core needle biopsy, and could be useful for diagnosis of PC. Molecular biomarkers (BMs) in FNA‐samples can be assessed for prediction, eg of immunotherapy efficacy before treatment as well as at treatment decision time points during disease progression.Methods: In the present pilot study, the expression levels of 151 BM proteins were analysed by proximity extension assay in FNA‐samples from 16 patients, including benign prostate lesions (n = 3) and cancers (n = 13). An ensemble data analysis strategy was applied using several machine learning models.Results: Twelve potentially predictive BM proteins correlating with International Society of Urological Pathology grade groups were identified, among them vimentin, tissue factor pathway inhibitor 2, and integrin beta‐5. The validity of the results was supported by network analysis that showed functional associations between most of the identified putative BMs. We also showed that multiple immune checkpoint targets can be assessed (eg PD‐L1, CD137, and Galectin‐9), which may support the selection of immunotherapy in advanced PC. Results are promising but need further validation in a larger cohort.Conclusions: Our pilot study represents a “proof of concept” and shows that multiplex profiling of potential diagnostic and predictive BM proteins is feasible on tumour material obtained by FNA sampling of prostate cancer. Moreover, our results demonstrate that an ensemble data analysis strategy may facilitate the identification of BM signatures in pilot studies when the patient cohort is limited.

11 January 2025 in PharmacoEconomics
Verified
Journal Article
Open access
PDF file
AFAdam Fridhammar
Adam Fridhammar
OFOskar Frisell
Oskar Frisell
KWKarin Wahlberg
Karin Wahlberg
EBEmelie Berglund
Emelie Berglund
PRPontus Röbeck
Pontus Röbeck
SPSofie Persson
Sofie Persson
Background The Prostatype score (P-score) is a prognostic biomarker that integrates a three-gene (IGFBP3, F3, and VGLL3) signature derived from prostate biopsy samples, with key clinical parameters, including prostate-specific antigen (PSA) levels, Gleason grade, and tumor stage at diagnosis. The test has demonstrated superior predictive accuracy for prostate cancer outcomes compared with traditional risk categorization systems such as D’Amico. Notably, it reclassifies a higher proportion of patients into the low-risk category, making them eligible for active surveillance. This study assessed the cost-effectiveness of the P-score in comparison with D’Amico and the Swedish National Prostate Cancer Register (NPCR) risk categorization systems. Methods A two-step decision analytic model was developed. The model consisted of a decision tree-informed Markov structure estimating the lifetime outcomes of 60-year-old men with diagnosed prostate cancer. Prostate cancer was classified as low-risk, intermediate-risk, or high-risk using either the P-score or D’Amico. Initial therapy was based on observed treatment patterns from the Swedish NPCR. Costs (SEK, year 2022) and quality-adjusted life years (QALYs) were estimated from a healthcare perspective and discounted at 3% per year; incremental cost-effectiveness ratio (ICER) was the primary outcome. Results The P-score led to cost savings and generated an additional 0.19 QALYs compared with D’Amico. The added costs of the genetic test and higher costs of active surveillance and radiotherapy were counterbalanced by savings from reduced costs of surgery, treatment-related side-effects, and metastatic disease. The gain in QALYs was primarily due to the avoidance of metastatic disease and a reduction in treatment-related side-effects. Conclusions The results of this study suggest that the P-score is likely to be a cost-effective alternative to D’Amico for prognostic evaluation of newly diagnosed prostate cancer in Sweden and compared with NPCR when health-related quality of life was included.

21 November 2025 in Medical Image Analysis
Verified
Journal Article
Open access
PFPatrick Fuhlert
Patrick Fuhlert
FWFabian Westhaeusser
Fabian Westhaeusser
EDEsther Dietrich
Esther Dietrich
MLMaximilian Lennartz
Maximilian Lennartz
RKRobin Khatri
Robin Khatri
SBStefan Bonn
Stefan Bonn
The histopathological evaluation of biopsies by human experts is a gold standard in clinical disease diagnosis. While recent artificial intelligence-based (AI) approaches have reached human expert-level performance, they often display shortcomings caused by variations in sample preparation, limiting clinical applicability. This study investigates the impact of data variation on AI-based histopathological grading and explores algorithmic approaches that confer prediction robustness. To evaluate the impact of data variation in histopathology, we collected a multicentric, retrospective, observational prostate cancer (PCa) trial consisting of six cohorts in 3 countries with 25,591 patients, 83,864 images. This includes a high-variance dataset of 8,157 patients and 28,236 images with variations in section thickness, staining protocol, and scanner. This unique training dataset enabled the development of an AI-based PCa grading framework by training on patient outcome, not subjective grading. It was made robust through several algorithmic adaptations, including domain adversarial training and credibility-guided color adaptation. We named the final grading framework PCAI. We compare PCAI to a BASE model and human experts on three external test cohorts, comprising 2,255 patients and 9,437 images. Variations in sample processing, particularly section thickness and staining time, significantly reduced the performance of AI-based PCa grading by up to 8.6 percentage points in the event-ordered concordance index (EOC-Index) thus highlighting serious risks for AI-based histopathological grading. Algorithmic improvements for model robustness, credibility, and training on high-variance data as well as outcome-based severity prediction give rise to robust models with grading performance surpassing experienced pathologists. We demonstrate how our algorithmic enhancements for greater robustness lead to significantly better performance, surpassing expert grading on EOC-Index and 5-year AUROC by up to 21.2 percentage points.

10 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FWFabian Westhaeusser
Fabian Westhaeusser
PFPatrick Fuhlert
Patrick Fuhlert
EDEsther Dietrich
Esther Dietrich
MLMaximilian Lennartz
Maximilian Lennartz
RKRobin Khatri
Robin Khatri
SBStefan Bonn
Stefan Bonn
Background Prostate cancer (PCa) is among the most common cancers in men and its diagnosis requires the histopathological evaluation of biopsies by human experts. While several recent artificial intelligence-based (AI) approaches have reached human expert-level PCa grading, they often display significantly reduced performance on external datasets. This reduced performance can be caused by variations in sample preparation, for instance the staining protocol, section thickness, or scanner used. Another limiting factor of contemporary AI-based PCa grading is the prediction of ISUP grades, which leads to the perpetuation of human annotation errors. Methods We developed the prostate cancer aggressiveness index (PCAI), an AI-based PCa detection and grading framework that is trained on objective patient outcome, rather than subjective ISUP grades. We designed PCAI as a clinical application, containing algorithmic modules that offer robustness to data variation, medical interpretability, and a measure of prediction confidence. To train and evaluate PCAI, we generated a multicentric, retrospective, observational trial consisting of six cohorts with 25,591 patients, 83,864 images, and 5 years of median follow-up from 5 different centers and 3 countries. This includes a high-variance dataset of 8,157 patients and 28,236 images with variations in sample thickness, staining protocol, and scanner, allowing for the systematic evaluation and optimization of model robustness to data variation. The performance of PCAI was assessed on three external test cohorts from two countries, comprising 2,255 patients and 9,437 images. Findings Using our high-variance datasets, we show how differences in sample processing, particularly slide thickness and staining time, significantly reduce the performance of AI-based PCa grading by up to 6.2 percentage points in the concordance index (C-index). We show how a select set of algorithmic improvements, including domain adversarial training, conferred robustness to data variation, interpretability, and a measure of credibility to PCAI. These changes lead to significant prediction improvement across two biopsy cohorts and one TMA cohort, systematically exceeding expert ISUP grading in C-index and AUROC by up to 22 percentage points. Interpretation Data variation poses serious risks for AI-based histopathological PCa grading, even when models are trained on large datasets. Algorithmic improvements for model robustness, interpretability, credibility, and training on high-variance data as well as outcome-based severity prediction gives rise to robust models with above ISUP-level PCa grading performance.